American Medicines Company, PBC
A U.S.-based, public-benefit company aiming to re-establish high-volume domestic production of generic oral solid dosage (OSD) medicines. The organization emphasizes continuous manufacturing, in-line/at-line analytical testing and automation, transparent sourcing and pricing, and supply-chain resilience (including surge capacity) to supply the U.S. market and support strategic stockpiles.
Industries
N/A
Products
Planned domestic portfolio of generic OSD medicines
A targeted portfolio of oral solid dose generic medicines including 18 of the top 40 prescribed molecules (as listed on relevant formulary sources), with a production target of 10 billion units within the first four years.
Planned domestic portfolio of generic OSD medicines
A targeted portfolio of oral solid dose generic medicines including 18 of the top 40 prescribed molecules (as listed on relevant formulary sources), with a production target of 10 billion units within the first four years.
Services
Domestic high-volume manufacturing of generic oral solid dosage medicines
Establish and operate manufacturing capacity to produce high-volume generic OSD products for exclusive supply to the U.S. market, including surge capacity for strategic stockpiles.
Domestic high-volume manufacturing of generic oral solid dosage medicines
Establish and operate manufacturing capacity to produce high-volume generic OSD products for exclusive supply to the U.S. market, including surge capacity for strategic stockpiles.
Expertise Areas
- Generic oral solid dosage (OSD) manufacturing
- Continuous manufacturing and process automation
- Formulation and process development for generics
- Analytical quality control and product testing
Key Technologies
- Continuous manufacturing for OSD
- In-line / at-line analytical testing (process analytical technology)
- Process automation and control systems
- 3D printing for packaging